OptiRTP has scheduled meetings with two established New Zealand pharmaceutical companies in January 2026 to discuss potential co-therapy applications for its Optimum Bio Sound Therapy (OBST) neuromodulation platform.
Author Archive
OptiRTP CEO Jon Doherty and Founder & CTO Bogdan Anich attended a networking function with Chris Seed, New Zealand’s Ambassador-Designate to the United States, on 4 December 2025.
OptiRTP presented its Optimum Bio Sound Therapy (OBST) platform to approximately 50–60 strength and conditioning coaches, sport scientists, medical professionals, and academics at the inaugural NZSCA-SPRINZ Strength & Conditioning Practitioners Day on 18 November 2025.
OptiRTP presented its U.S. market entry strategy and clinical validation roadmap to more than 40 current and prospective investors at a private briefing held at Buddle Findlay’s Auckland office on 6 November 2025.
OptiRTP CEO Jon Doherty attended the Japanese Chamber of Commerce of Auckland (Nisuikai) seminar on 21 October 2025, as the company continues building connections ahead of its planned Japan market entry from 2027.
OptiRTP CEO Jon Doherty presented the company’s Optimum Bio Sound Therapy (OBST) platform to a Utah state delegation led by Governor Spencer J. Cox at an AmCham business briefing held during Auckland Start-Up Week on 20 October 2025.
The American Chamber of Commerce in New Zealand (AmCham) has published a feature on OptiRTP, profiling the company’s Optimum Bio Sound Therapy (OBST) platform as an example of New Zealand medical technology expanding into international markets.
OptiRTP has joined the Japan New Zealand Business Council (JNZBC), a network of New Zealand and Japanese organisations focused on bilateral trade and business relationships.